$0.72
arrow_drop_up2.85%Key Stats | |
---|---|
Open | $0.76 |
Prev. Close | $0.00 |
EPS | - |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $0.00 |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 0.70 | 0.81 |
52 Week Range | 0.70 | 4.14 |
Ratios | |
---|---|
Revenue | - |
EPS | - |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Immatics Announces Pricing of $150 Million Public Offering
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
Immatics Announces Second Quarter 2024 Financial Results and Business Update
Memo Therapeutics AG appoints Paul Carter as Chairperson - GlobeNewswire